Abiopharma

🔍 Carlson Christopher (Executive)

Company: RB GLOBAL INC. (RBA)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 3 shares of Dividend Equivalent Rights (2024 RSUs) (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: false | shares_owned_after: 71.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Acquired 2 shares of Dividend Equivalent Rights (2025 RSUs) (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: false | shares_owned_after: 14.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 4 shares of Dividend Equivalent Rights (2026 RSUs) (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: false | shares_owned_after: 4.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: Each dividend equivalent right represents a contingent right to receive the economic equivalent of one RBA common share. The dividend equivalent rights accrued in respect of the 2024 grant of restricted share units (RSU), and become exercisable proportionately with the restricted share units to which they relate.
• F2: Each dividend equivalent right represents a contingent right to receive the economic equivalent of one RBA common share. The dividend equivalent rights accrued in respect of the 2025 grant of restricted share units (RSU), and become exercisable proportionately with the restricted share units to which they relate.
• F3: Each dividend equivalent right represents a contingent right to receive the economic equivalent of one RBA common share. The dividend equivalent rights accrued in respect of the 2026 grant of restricted share units (RSU), and become exercisable proportionately with the restricted share units to which they relate.